knowledge -WSS

knowledge

author：fashion 2025-10-02 00:18:27 - browse：487

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Pharma patents targeted by Biden in move to slash drug prices

WSS

What causes an itch? Researchers may have solved the mystery

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Top private equity targets in 2023: cardiology, clinical trials, lasers

Patients' immediate access to test results puts radiologists in a bind

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Padmanee Sharma of MD Anderson at center of lawsuit over credit

explore

knowledge

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Bernie brings in new pharma CEOs to talk drug prices

Activists slam private health insurers over coverage restrictions

Texas Medical Board asked to define abortion emergency exception

Trump demands the U.S. pay no more for drugs than other countries … again

STAT letters to the editor on burnt

Novavax promises a turnaround & Lilly roils the obesity market

SCOTUS to consider access to abortion pill mifepristone

As demand for Covid shots wanes, Moderna seeks its next success

The woman behind the Dana Farber

leisure time

Roche to buy Carmot Therapeutics, developer of obesity drugs

Roche to buy Carmot Therapeutics, developer of obesity drugs

CMS should re

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Top private equity targets in 2023: cardiology, clinical trials, lasers

What causes an itch? Researchers may have solved the mystery

focus

focus

knowledge

hotspot